Chromocell Therapeutics Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations
FOR THE THREE MONTHS ENDED MARCH 31, 2024 and 2023
| For the Three Months Ended | For the Three Months Ended | |
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| OPERATING EXPENSES | ||
| General and administrative expenses | $787,561 | $477,630 |
| Research and development | 466,606 | 186,117 |
| Professional fees | 679,815 | 250,836 |
| Total operating expenses | 1,933,982 | 914,583 |
| NET LOSS FROM OPERATIONS | (1,933,982) | (914,583) |
| OTHER (EXPENSE) INCOME | ||
| Interest expense | (628,348) | (51,978) |
| Total other (expense) income | (628,348) | (51,978) |
| Net loss before provision for income taxes | (2,562,330) | (966,561) |
| Provision for income taxes | — | — |
| NET LOSS | $(2,562,330) | $(966,561) |
| Net loss per common share - basic and diluted | $(0.55) | $(0.87) |
| Weighted average number of common shares outstanding during the year - basic and diluted | 4,690,989 | 1,111,112 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.